Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2018-04-02 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
累积投票制度实施细则
Governance Information Classification · 95% confidence The document is titled as the "Implementation Rules for the Cumulative Voting System" of a company, detailing the procedures and regulations for electing directors and supervisors using cumulative voting. It includes legal references, nomination processes, voting methods, and election results handling. There is no financial data, no report of financial performance, no announcement of voting results, nor any indication of a meeting presentation or management change. The document is a governance-related internal regulation aimed at shareholders and company governance structure. Therefore, it fits best under Governance Information (CGR). The document length is 3717 characters, which is relatively short but contains substantive governance rules, not just an announcement or notice.
2018-04-02 Chinese
关于修订公司章程的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of 普莱柯生物工程股份有限公司 regarding amendments to the company's articles of association (公司章程). It details specific changes to the company's governance structure and operational scope, including definitions of senior management and business scope adjustments. The document is an official disclosure of board resolutions and changes to governance documents, not a full report or financial statement. It does not contain financial data or detailed management discussion but focuses on governance changes. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related governance updates.
2018-04-02 Chinese
章程
Governance Information Classification · 100% confidence The document is titled "公司章程" which translates to "Company Articles of Association" or "Company Bylaws." It contains detailed sections on company governance, shareholder rights, board of directors, management, financial accounting, and other corporate organizational rules. The content is legal and regulatory in nature, focusing on the internal rules and structure of the company rather than financial results or announcements. There is no indication that this is an annual report, earnings release, or any other financial filing. It is a governance document outlining the company's internal rules and practices. Therefore, the appropriate classification is Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the bylaws, not just an announcement or summary.
2018-04-02 Chinese
关于放弃参股公司增资优先认购权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a related party transaction where the company (普莱柯生物工程股份有限公司) is waiving its preemptive rights to subscribe to a capital increase in an associate company (北京中科基因技术有限公司). It includes information about the transaction, the parties involved, financial data of the associate, approvals by the board and independent directors, and the need for shareholder approval. The document is not a financial report, earnings release, or regulatory certification. It is a formal announcement of a capital/financing update related to shareholding and investment in an associate company. The document length is 3660 characters, which is relatively short but contains substantive transaction details. Therefore, the best fitting category is Capital/Financing Update (CAP).
2018-04-02 Chinese
关于对暂时闲置募集资金和自有资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普莱柯生物工程股份有限公司 regarding the use of temporarily idle raised funds and own funds for cash management through purchasing financial products. It details the types, amounts, risk ratings, and expected returns of various financial products purchased, as well as risk control measures and the impact on company operations. The document is a formal disclosure of financing activities related to cash management and investment of idle funds, not a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion of results, nor is it a regulatory certification or voting result. The content fits best with updates on company fundraising, financing activities, or capital structure changes, which corresponds to the Capital/Financing Update (CAP) category.
2018-03-09 Chinese
关于对暂时闲置募集资金和自有资金进行现金管理的实施公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普莱柯生物工程股份有限公司 regarding the use of temporarily idle raised funds and own funds for cash management through purchasing various financial products. It details the types of financial products purchased, amounts, expected returns, risk ratings, and risk control measures. The document includes specific transaction details and dates but does not present comprehensive financial statements or a full financial report. It is a disclosure about financing activities related to cash management and investment of idle funds rather than a full annual or interim report. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about financing activities, not just a brief announcement or certification, so it is not RPA or RNS.
2018-01-30 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.